New Treatment Authorized

Mexico's Federal Commission for the Protection against Sanitary Risk (Cofepris) approved a new therapeutic option in June for managing hidradenitis supurativa, a chronic inflammatory skin disease colloquially known in Mexico as inverse acne or golondrinos. The agency issued the health registry this month based on clinical evidence of safety and efficacy reviewed internally.

The approval broadens the treatment landscape for a condition affecting roughly 1% of the population according to international clinical literature, though diagnosis often gets delayed due to confusion with other common skin conditions. The decision slots within Cofepris's 2026 authorization of 111 new medications across oncology, mental health, rheumatological diseases, and dermatology.

What Hidradenitis Supurativa Is

The disease manifests in friction zones like armpits, groin, buttocks, and under the breasts, with deep nodules and painful fistulas that can leave permanent scarring. Patients experience intense pain, recurring abscesses, and significant quality-of-life impact.

Regulatory Progress

In the first quarter of 2026 alone, Cofepris approved 111 drug registries, 29 clinical trials, and 468 medical device registries, totaling 608 health products.

Next Steps for Patients

The new therapy joins existing biologics in the Mexican market and targets patients with moderate to severe cases under specialized medical supervision. Real access now depends on distributors deciding pharmacy availability and potential inclusion in Mexico's public health formulary. Patient advocacy groups say that decision will determine whether this approval translates into actual treatment access in coming months.

Sources